KEEP ALERTS SET FOR A BREAK OF $105, WHICH COULD RESULT IN A VERY NASTY FALL BACK DOWN TO THE GAP UP LEVEL $75, AVERAGE ANALYSTS ESTIMATE $162.20 AVERAGE ANALYSTS RECOMMENDATION BUY
COMPANY PROFILE Ascendis Pharma A/S is a biopharmaceutical company, which engages in the development of drug candidates. Through its TransCon technology, it develops a pipeline of sustained release prodrug therapies including endocrinology product candidates to support the market. The company was founded by Jan Moller Mikkelsen and Harald Rau in September 2006 and is headquartered in Hellerup, Denmark.